In trials of Eli Lilly's next-gen obesity drug, participants are running into an issue they never expected: They are losing too much weight.
 Molly Ferguson for STAT
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs In ongoing trials of Eli Lilly's next-generation obesity drug, several participants are running into an issue they never expected: They are losing too much weight. The concern is an outgrowth of drug companies' race to the bottom — an intense competition to develop drugs that can deliver greater and greater topline weight loss. Read more. By Elaine Chen |
|
 Photo illustration: Christine Kao/STAT; Photo: Adobe
The 'GRAS' loophole lets untested additives into Americans' food. Can RFK Jr. close it? Between 2001 and 2019, the portion of packaged foods containing additives grew from 49.6% to 59.5%. "GRAS has been abused, and it's ripe for reform," said Stephen Ostroff, former acting FDA commissioner and deputy commissioner for foods. Read more. By Sarah Todd and Lizzy Lawrence
 Steve Helber/AP
The lasting human impact of Trump funding freeze: An 86-year-old's ride to dialysis now feels tenuous For Nancy Hastings, the face of the federal government is the young man who picks her up every Monday, Wednesday, and Friday at 5:45 a.m. to drive her to dialysis. She's 86, and frail, and he stands behind her in the smoky half-light as she maneuvers down her front stairs. Then suddenly, in late January, word came that he was gone. Read more. By Eric Boodman
In case you missed it |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2025, All Rights Reserved. | |
|
No comments